Inmune Bio Shares Continue Downward Trajectory Amidst Weak Fundamentals

Inmune Bio’s stock extended its decline in Friday’s trading session, closing at $2.01 after a drop of 0.99%. The day’s trading pattern, which saw shares fluctuate between a low of $1.99 and a high of $2.08, highlighted significant intraday volatility of 4.52%. A particularly concerning signal for investors was the sharp drop in trading volume, which fell by 38,000 shares, indicating waning market interest as the price continues to fall.

Fundamental Pressures Mount

The downward pressure on the stock is supported by concrete fundamental challenges. The company’s August earnings report revealed a quarterly loss of $24.5 million, marking a substantial deterioration compared to the previous year. Investor sentiment was further dampened by disappointing results from the MINDFuL Phase 2 study for Alzheimer’s disease. Additionally, the company underwent a leadership transition, with David Moss taking over as CEO following the departure of RJ Tesi.

Despite the negative backdrop, there are some positive developments. Inmune Bio successfully completed the first commercial pilot production of CORDStrom™. The company is targeting mid-2026 for submitting regulatory applications for the treatment of RDEB. Furthermore, the INKmune® program has demonstrated promising safety data in early-stage studies.

Should investors sell immediately? Or is it worth buying Inmune Bio?

Technical Indicators Flash Warning Signs

From a technical analysis perspective, the picture is unequivocally bearish. The stock has been in a pronounced downtrend since August 19, 2025, having already shed 16.25% of its value and is currently viewed as a clear sell candidate. The Fear & Greed Index reading of 39 points to a market dominated by fear.

Key technical observations include:
* The positioning of moving averages confirms the negative trend, with the 20-day average sitting well below the 60-day average.
* One forecast suggests the potential for an additional 25.63% decline over the coming three months.
* There is a 90% probability that the share price will trade within a range of $1.00 to $1.91.

Divergent Analyst Views Create Uncertainty

The critical question is whether the stock can reverse its current downward momentum. Analyst opinions are sharply divided, with price targets ranging from a conservative $2.02 to a highly optimistic $22.05. The consensus target sits at $12.52. However, the prevailing market mood is currently disregarding these longer-term prospects, with weak technicals and fundamental data driving trading activity. A meaningful trend reversal will likely require positive clinical trial results or other significant positive corporate announcements.